Robust growth forecast for renal cell carcinoma market

The renal cell carcinoma drug market will experience robust 3.7% annual growth from 2010 to 2020 in the leading markets of the USA, France, Germany, Italy, Spain, the UK and Japan, according to health care advisory firm Decision Resources. Market growth will be driven mainly by the uptake of GlaxoSmithKline’s Votrient (pazopanib, the launches of premium-priced emerging therapies, rising treatment rates and an increase in the number of diagnosed patients.

DR’s Pharmacor advisory service titled Renal Cell Carcinoma finds that, in 2010, angiogenesis inhibitors captured 76% of the market, with Pfizer’s Sutent (sunitinib maleate) accounting for more than half of sales in this class. Although angiogenesis inhibitors will continue to dominate the market through 2020, Sutent will account for only 14% of sales in this class in 2020, owing to the high uptake of Votrient and the launch of Pfizer’s axitinib and Aveo Pharmaceuticals/Astellas Pharma/Kyowa Hakko Kirin’s tivozanib, the report projects.

Axitinib to become RCC market leader with sales of $564 million